Drug
GST-HG171/Ritonavir
GST-HG171/Ritonavir is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants
NCT06087055
unknownphase_1
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
NCT06084507
completedphase_2
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
NCT05656443
Clinical Trials (3)
Showing 3 of 3 trials
NCT06087055Phase 1
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants
NCT06084507Phase 1
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
NCT05656443Phase 2
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3